Josef Huntington

Josef Huntington

Auto-generated profile, based on publicly available information

Josef Huntington

King's College London, British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine and Sciences, The James Black Centre, 125 Coldharbour Lane, London, SE5 9NU, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
DBDaniel Ian Bromage
Daniel Ian Bromage
STSilvia C. Trevelin
Silvia C. Trevelin
JHJosef Huntington
Josef Huntington
VYVictoria X. Yang
Victoria X. Yang
AMAnanya Muthukumar
Ananya Muthukumar
ASAjay M Shah
Ajay M Shah
Background: There is compelling evidence implicating dysregulated inflammation in the mechanism of ventricular remodeling and heart failure (HF) after MI. The transcription factor nuclear factor erythroid-derived 2-like 2 (Nrf2, encoded by Nfe2l2) is a promising target in this context since it impedes transcriptional upregulation of pro-inflammatory cytokines and is anti-inflammatory in various murine models. Objectives: We aimed to investigate the contribution of Nrf2 to the inflammatory response after experimental myocardial infarction (MI). Methods: We subjected Nrf2−/− mice and wild type (WT) controls to permanent left coronary artery (LCA) ligation. The inflammatory response was investigated with fluorescence-activated cell sorting (FACS) analysis of peripheral blood and heart cell suspensions, together with qRT-PCR of infarcted tissue for chemokines and their receptors. To investigate whether Nrf2-mediated transcription is a dedicated function of leukocytes, we interrogated publicly available RNA-sequencing (RNA-seq) data from mouse hearts after permanent LCA ligation for Nrf2-regulated gene (NRG) expression. Results: FACS analysis demonstrated a profoundly inflamed phenotype in the hearts of global Nrf2−/− mice as compared to WT mice after MI. Moreover, infarcted tissue from Nrf2−/− mice displayed higher expression of mRNA coding for inflammatory cytokines, chemokines, and their receptors, including IL-6, Ccl2, and Cxcr4. RNA-seq analysis showed upregulated NRG expression in WT mice after MI compared to naive mice, which was significantly higher in bioinformatically isolated CCR2+ cells. Conclusions: Taken together, the results suggest that Nrf2 signalling in leukocytes, and possibly CCR2+ monocytes and monocyte-derived cardiac resident macrophages, may be potential targets to prevent post-MI ventricular remodeling.

2 December 2025 in Circulation
Verified
Journal Article
Closed access
MTMateusz Tomczyk
Mateusz Tomczyk
IKIzabela Kraszewska
Izabela Kraszewska
GLGang Li
Gang Li
MHMatthew Hayes
Matthew Hayes
LVLuca Venditti
Luca Venditti
MGMauro Giacca
Mauro Giacca

1 April 2020 in Journal of the Endocrine Society
Verified
Journal Article
Open access
JHJosef Huntington
Josef Huntington
RRRachel Robertson
Rachel Robertson
GDGurtej K Dhoot
Gurtej K Dhoot
IMImelda M McGonnell
Imelda M McGonnell
CWCaroline Wheeler-Jones
Caroline Wheeler-Jones
AMAbir Mukherjee
Abir Mukherjee
Follistatin-like 3 (FSTL3), a glycoprotein that inhibits transforming growth factor-β (TGFβ) ligands such as activin, is expressed highly in the placenta and other vascular tissues. In addition, FSTL3 is strongly induced in pre-eclamptic placenta. To test the hypothesis that FSTL3 function is required for capillary bed structure and function we studied the placenta in FSTL3 gene deleted mice (FSTL3 KO). We have previously shown that FSTL3 deletion produces striking defects in the placenta when compared to WT. Placental size increases significantly in comparison to WT, at 16.5 and 18.5 dpc, with concurrent reduction in placental efficiency at 18.5 dpc. Histological analyses reveal structural differences in placental junctional zones in FSTL3 KO placenta compared to WT. Morphometric analyses show that the labyrinth area compared to the placenta area is significantly reduced in FSTL3 KO mice. We also found that activin-responsive FSTL3-synexpression genes are upregulated in FSTL3 KO placenta. Of these, EPHB4 protein is induced in the placenta along with its ligand EphrinB2. Here we show that FSTL3 deletion leads to endothelial cell expansion but reduction in blood vessel density along with increased extracellular matrix deposition. Further investigation of the placental phenotype revealed differential expression patterns of desmin and cytokeratin protein, reduced von Willebrand factor (VWF) and increased CD31 and VEGFR2 labelling within FSTL3 KO mice placental labyrinths. To identify mechanisms that might lead to the altered placental development in FSTL3 KO mice qPCR analyses were performed. Our results identified differences in the expression of crucial transcripts, such as Cdh5, Pgf, Fra1and Cited1, that are associated with the regulation of vascular biology. Additionally, we find increased Histone3 and SMAD2 phosphorylation in FSTL3 KO placenta indicating increased proliferation and activin signalling, respectively. These findings suggest that the balance between cellular proliferation and differentiation might be altered in the absence of FSTL3. Thus, we conclude that FSTL3 function, at least partly through the inhibition of activin action, is necessary for normal placental circulation and development.

25 July 2026 in International Journal of Biological Macromolecules
Verified
Journal Article
Open access
HGHussein Hamdy Genedy
Hussein Hamdy Genedy
TDThierry Delair
Thierry Delair
JHJosef Huntington
Josef Huntington
GRGiorgia Rizzari
Giorgia Rizzari
Jordy KockenJordy Kocken
Jordy Kocken
AMAlexandra Montembault
Alexandra Montembault
Ischemic heart disease is the main cause of death in developed countries, and full recovery remains unachievable. A potential cure can be based on utilizing miRNAs capable of triggering cardiac regeneration by stimulating cardiomyocyte proliferation. However, to deliver miRNAs efficiently, nanocarriers are required for protection from rapid cleavage in the extracellular milieu and successful uptake by cardiomyocytes. Here, we present biocompatible chitosan nanoparticles, formulated via a green polyelectrolyte complexation process, and efficiently loaded with miR199a-3p. Their safety and therapeutic potential were evaluated in vitro and in vivo. To enhance cardiac accumulation, we further explored the functionalization of these nanoparticles with tannic acid, a polyphenolic compound that exhibits favored cardiac targeting and sustained retention. Thus, we have optimized the miR-loaded chitosan-based formulation to achieve tunable sizes (100-300 nm) while maintaining high biocompatibility with HL-1 cardiomyocytes and primary murine or rat cardiomyocytes. Notably, miRNA-loaded nanoparticles boosted cardiomyocyte proliferation by up to 75%. Confocal microscopy confirmed successful uptake by cardiomyocytes. In vivo, no mortality or adverse effects were observed during the 4-day observation period, with miRNA expression increasing up to sixfold and target gene downregulation reaching 50%. These findings establish a proof of concept that chitosan-based polyelectrolyte complexes can serve as a safe and effective nanoplatform for delivering regenerative miRNAs to the heart, paving the way for next-generation cardiac therapies.